Esphera’s platform technology generates exosomes that deliver defined payloads to targeted cells in the body.

The technology targets several kinds of cells, including tumour cells and immune cells, and deliver a variety of therapeutic payloads, including enzymes and RNAs.

It is designed to enhance existing immunotherapy and vaccine technologies and aid in gene therapy, enzyme replacement therapy and cancer immunotherapy.